이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Hangzhou Biotest BiotechLtd 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Shujiang Wu

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	2.1%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

Recent updates

We Think You Can Look Beyond Hangzhou Biotest BiotechLtd's (SHSE:688767) Lackluster Earnings

May 03

CEO

Shujiang Wu (47 yo)

no data

테뉴어

CN¥2,580,400

보상

Mr. Shujiang Wu serves as General Manager and Director at Hangzhou Biotest Biotech Co.,Ltd.

Hangzhou Biotest BiotechLtd 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Hangzhou Biotest Biotech Co.,Ltd., Annual General Meeting, May 17, 2024

Hangzhou Biotest Biotech Co.,Ltd., Annual General Meeting, May 17, 2024

No independent directors

No independent directors

Recent updates

Hangzhou Biotest Biotech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024

We Think You Can Look Beyond Hangzhou Biotest BiotechLtd's (SHSE:688767) Lackluster Earnings

Hangzhou Biotest Biotech Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.11 in 1Q 2023)

Hangzhou Biotest Biotech Co.,Ltd., Annual General Meeting, May 17, 2024

Hangzhou Biotest Biotech Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥1.04 (vs CN¥7.25 in FY 2022)

Now 24% undervalued

Hangzhou Biotest Biotech Co.,Ltd. (SHSE:688767) announces an Equity Buyback for CNY 100 million worth of its shares.

Hangzhou Biotest Biotech Co.,Ltd. (SHSE:688767) announces an Equity Buyback for CNY 100 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥1.31 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.48 (vs CN¥2.36 in 2Q 2022)

Investor sentiment deteriorates as stock falls 19%

Hangzhou Biotest Biotech Co.,Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Now 24% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 17%

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥7.25 (vs CN¥9.62 in FY 2021)

Full year 2022 earnings released: EPS: CN¥7.48 (vs CN¥9.62 in FY 2021)

No independent directors

Third quarter 2022 earnings released: EPS: CN¥1.31 (vs CN¥1.41 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥2.36 (vs CN¥4.20 in 2Q 2021)

No independent directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

CEO

테뉴어

보상